摘要
目的探讨不同剂量沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病(COPD)患者肺功能及炎性因子的影响。方法选取2019年5月—2020年5月收治的120例COPD为研究对象,按照沙美特罗替卡松粉吸入剂给药剂量不同分为观察组与对照组,每组60例。两组均予基础治疗,同时对照组和观察组分别给予沙美特罗替卡松粉吸入剂50μg/250μg和50μg/500μg治疗。比较两组治疗6个月后临床疗效及用药期间不良反应发生情况,比较两组治疗前及治疗6个月后血清指标[肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、C反应蛋白(CRP)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、核因子-κB(NF-κB)、白三烯B4(LTB4)]、肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)]及6 min步行距离(6MWD)。结果观察组临床疗效总有效率高于对照组(P<0.05)。治疗后,两组FEV1、FVC、FEV1/FVC及6MWD高于治疗前,且观察组高于对照组(P<0.05)。治疗后,两组血清TNF-α、IL-8、CRP、GM-CSF、NF-κB、LTB4水平低于治疗前,且观察组低于对照组(P<0.05)。两组用药期间不良反应发生率比较差异无统计学意义(P>0.05)。结论沙美特罗替卡松粉吸入剂能够明显改善COPD患者肺功能及炎性因子水平,吸入剂量为50μg/500μg时治疗效果更好,且无明显不良反应发生。
Objective To explore effects of different doses of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation on lung function and inflammatory factors in patients with chronic obstructive pulmonary disease(COPD).Methods A total of 120 patients with COPD admitted between May 2019 and May 2020 were selected as research subjects,and they were divided into observation group(n=60)and control group(n=60)according to different doses of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation.Both groups were given basic treatments,and then control and observation groups were respectively given Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation at a dose of 50μg/250μg and 50μg/500μg simultaneously.Clinical efficacy after treatment for 6 months and occurrence of adverse reactions during the treatment were compared between two groups.Serum indexes[tumor necrosis factor-α(TNF-α),interleukin-8(IL-8),C-reactive protein(CRP),granulocyte-macrophage colony stimulating factor(GM-CSF),nuclear factor-κB(NF-κB),leukotriene B4(LTB4)],indicators of lung function[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC]and 6-min walking distance(6MWD)before and after treatment for 6 months were compared between two groups.Results The total effective rate in observation group was significantly higher than that in control group(P<0.05).After treatment,levels of FEV1,FVC,FEV1/FVC and 6MWD were significantly higher than those before treatment in two groups,and the levels in observation group were significantly higher than those in control group(P<0.05).After treatment,serum levels of TNF-α,IL-8,CRP,GM-CSF,NF-κB,and LTB4 were significantly lower than those before treatment in two groups,and the levels in observation group were significantly lower than those in control group(P<0.05).There was no significant difference in incidence rate of adverse reactions during the medication between two groups(P>0.05).Conclusion Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation may significantly improve lung function and levels of inflammatory factor in patients with COPD.When the inhaled dose is 50μg/500μg,the therapeutic effect is better without obvious adverse reactions.
作者
高岩
赵晓倩
关艳红
郭秀清
彭新华
岳燕军
王倩
曹文娟
邹晓
GAO Yan;ZHAO Xiao-qian;GUAN Yan-hong;GUO Xiu-qing;PENG Xin-hua;YUE Yan-jun;WANG Qian;CAO Wen-juan;ZOU xiao(Department of Clinical Laboratory,the First Hospital of Zhangjiakou City,Zhangjiakou,Hebei 075000,China;Department of Pharmacy,the Maternal and Child Health Care Hospital of Shijiazhuang City,Shijiazhuang 050000,China;Department of Internal Medicine,Great Wall Hospital of Integrated Traditional Chinese and Western Medicine,Shijiazhuang 050000,China)
出处
《临床误诊误治》
CAS
2022年第2期20-24,共5页
Clinical Misdiagnosis & Mistherapy
基金
河北省医学科学研究重点课题计划项目(20211224)。
关键词
肺疾病
慢性阻塞性
沙美特罗替卡松
肺功能
肿瘤坏死因子α
白细胞介素-8
核因子-ΚB
白三烯B4
Pulmonary disease,chronic obstructive
Salmeterol xinafoate and fluticasone propionate
Pulmonary function
Tumor necrosis factor-α
Interleukin-8
Nuclear factor-κB
Leukotriene B4
